MedTrace Logo

C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration

NCT04107740 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2023-07-24

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy and safety of C-Trelin OD Tablet 5mg(Taltirelin Hydrate) in Multicenter, randomized, double-blind, placebo-controlled clinical trial in patients with ataxia induced by spinocerebellar degeneration.

Conditions

  • Spinocerebellar Degeneration

Interventions

DRUG

C-Trelin OD Tab(5mg Taltirelin Hydrate)

BID, 10mg per day, for 24 weeks

DRUG

Placebo

BID, 10mg per day, for 24 weeks

Sponsors & Collaborators

  • HLB Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Seong-beom Koh · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-04
Primary Completion
2021-02-08
Completion
2021-02-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04107740 on ClinicalTrials.gov